GO:0005102 signaling receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005102 signaling receptor binding is a molecular function defined as binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.
• It is the initial molecular event in receptor-mediated signal transduction, enabling ligands such as hormones, growth factors, neurotransmitters and viral proteins to engage receptors and trigger downstream signaling [1,2,3].
• Major receptor families involved include G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), cytokine receptors, nuclear hormone receptors and viral entry receptors [1,2,3,4].
• Dysregulation of signaling receptor binding underlies cancer, endocrine disorders, immune dysfunction and viral infections, making it a central target for therapeutic intervention [3,4,5,7].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect the causal role of receptor-ligand interactions in health and disease [5,6,8].
• EDITGENE provides end-to-end CRISPR services including knockout, point mutation, knock-in, overexpression cell models and CRISPR library screening to study signaling receptor binding at scale.
Description
Signaling receptor binding (GO:0005102) is a molecular function that describes the binding of a ligand or intracellular messenger to a specific site on a receptor molecule, thereby initiating a change in cell function. This term captures the essential first step in a vast array of signaling pathways, from G protein-coupled receptor (GPCR) activation by neurotransmitters to growth factor binding to receptor tyrosine kinases (RTKs) [1,3]. The specificity and affinity of these interactions determine the fidelity of signal transduction and are critical for normal physiology [2,4]. Researchers study signaling receptor binding to understand how cells sense and respond to their environment, how pathogens such as viruses engage host receptors, and how mutations in receptors or ligands contribute to disease [2,5,7]. The QuickGO definition emphasizes that the receptor is a macromolecule that combines with a hormone, neurotransmitter, drug or intracellular messenger, highlighting the broad chemical diversity of ligands. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease relevance and experimental methods for studying signaling receptor binding.
signaling receptor binding At A Glance
| GO ID | GO:0005102 |
|---|---|
| GO term | signaling receptor binding |
| Ontology | molecular_function |
| Synonym | receptor-associated protein activity, receptor binding, receptor ligand |
| Definition | Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
| Major function | Initiates receptor-mediated signal transduction by mediating ligand-receptor or messenger-receptor interactions. |
| Examples of receptors | GPCRs, RTKs, cytokine receptors, nuclear hormone receptors, viral entry receptors [1,2,3,4,7]. |
| Disease relevance | Cancer, endocrine disorders, immune dysfunction, viral infections [3,4,5,7]. |
| Research methods | CRISPR knockout/knock-in, binding assays, structural biology, signaling assays [1,2,5,6,8]. |
What Is GO:0005102?
In our own words, GO:0005102 signaling receptor binding refers to the molecular function of a protein or other molecule binding to a specific site on a receptor, where the receptor is a macromolecule that can bind hormones, neurotransmitters, drugs or intracellular messengers to trigger a cellular response. This function is synonymous with receptor-associated protein activity, receptor binding and receptor ligand activity. It is a molecular function term in the Gene Ontology, distinct from downstream signaling events, and it encompasses the physical interaction between a ligand (or an intracellular messenger) and its receptor, which is the prerequisite for receptor activation and subsequent signal transduction [1,2].
Why Is signaling receptor binding Important in Cell Biology?
Signaling receptor binding is fundamentally important because it is the molecular event that initiates nearly all intercellular communication and cellular responses to external cues. It governs processes as diverse as neurotransmission, hormone action, immune recognition and viral entry [1,2,3,4]. Understanding this function is essential for drug discovery, as many therapeutics target receptor-ligand interactions, and for deciphering disease mechanisms where mutations alter binding affinity or specificity [5,6,7].
• It is the first step in signal transduction for GPCRs, RTKs, cytokine receptors and nuclear receptors [1,3,4].
• It mediates hormone action, including insulin-like growth factor 1 (IGF1) and mineralocorticoid signaling [3,4].
• It is exploited by viruses to bind host receptors and initiate infection.
• Mutations in receptor or ligand genes that affect binding can cause cancer, endocrine disorders and immune deficiencies [3,5,7].
• It is a major target for therapeutic antibodies, small molecules and peptide drugs [1,6].
• CRISPR screens can identify novel receptor-ligand interactions and their functional consequences [5,8].
• It is critical for understanding growth hormone-releasing hormone receptor signaling and related endocrine pathways.
• It plays a role in immune signaling, including interferon-gamma related pathways in fish models.
• It is involved in TGF-beta superfamily signaling through Smad activation.
• It provides a basis for engineering synthetic receptors and ligand traps for research and therapy [1,2].
Molecular Mechanism of signaling receptor binding
Ligand recognition and binding specificity
In simple terms: The ligand must fit into a specific pocket on the receptor, like a key in a lock.
Signaling receptor binding begins with the specific recognition of a ligand by the receptor's extracellular or intracellular binding domain. For GPCRs, the ligand binds within a pocket formed by the transmembrane helices, while RTKs typically bind growth factors via extracellular immunoglobulin-like or cysteine-rich domains [1,3]. The binding specificity is determined by the complementary shape, charge and hydrophobic interactions between the ligand and the receptor binding site. This step is reversible and governed by affinity and kinetics, which dictate the duration and strength of the signal [1,2].
Conformational changes and receptor activation
In simple terms: Once the ligand binds, the receptor changes shape to pass the message inside the cell.
Ligand binding induces conformational changes in the receptor that propagate across the membrane or within the receptor complex. In GPCRs, agonist binding stabilizes an active conformation that promotes coupling to heterotrimeric G proteins. In RTKs, ligand binding typically induces receptor dimerization or oligomerization, leading to autophosphorylation of intracellular tyrosine kinase domains. Nuclear receptors undergo ligand-dependent conformational changes that release corepressors and recruit coactivators. These structural transitions are essential for converting the binding event into a biochemical signal.
Downstream signaling initiation
In simple terms: The activated receptor then switches on a chain of signaling proteins inside the cell.
Upon activation, the receptor engages downstream effectors. GPCRs activate G proteins, which modulate enzymes like adenylyl cyclase or phospholipase C. RTKs phosphorylate adaptor proteins such as GRB2 and SHC, leading to RAS-MAPK and PI3K-AKT pathway activation. Cytokine receptors activate JAK-STAT pathways. Nuclear receptors directly regulate transcription by binding to hormone response elements. In TGF-beta signaling, receptor activation leads to Smad phosphorylation and nuclear translocation. Each of these events is a direct consequence of the initial signaling receptor binding event.
Regulation and termination of binding
In simple terms: Cells have ways to turn off the signal, such as degrading the ligand or internalizing the receptor.
Signaling receptor binding is tightly regulated to prevent excessive or prolonged signaling. Mechanisms include receptor desensitization, internalization, and degradation, as well as ligand sequestration or degradation [1,2]. For example, GPCR kinases phosphorylate activated receptors, promoting arrestin binding and internalization. RTKs are downregulated by ubiquitination and lysosomal degradation. Viral receptor interactions can also be modulated by host defense mechanisms. These regulatory processes ensure that signaling is transient and appropriate to the cellular context.
Viral exploitation of signaling receptor binding
In simple terms: Some viruses use normal receptors to enter cells, like a thief using a key.
Many viruses have evolved to bind host signaling receptors or related molecules to gain entry. For instance, viruses can bind to specific cell surface receptors, triggering endocytosis or membrane fusion. This binding event mimics natural ligand-receptor interactions but leads to viral entry rather than normal signaling. Understanding these interactions is crucial for antiviral drug development and vaccine design.
Key Genes Involved in GO:0005102 signaling receptor binding
The following genes encode receptors, ligands or associated proteins that directly participate in signaling receptor binding (GO:0005102) and are widely studied in this context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor; binds catecholamines | Model GPCR for studying ligand binding and signaling |
| EGFR | Epidermal growth factor receptor; binds EGF | RTK model for cancer and signaling |
| IGF1R | Insulin-like growth factor 1 receptor; binds IGF1 | Endocrine and cancer signaling |
| NR3C2 | Mineralocorticoid receptor; binds aldosterone | Hypertension and electrolyte balance |
| GHRHR | Growth hormone-releasing hormone receptor; binds GHRH | Endocrine disorders and growth |
| IFNGR1 | Interferon gamma receptor 1; binds IFN-gamma | Immune signaling and host defense |
| TGFBR1 | TGF-beta receptor type 1; binds TGF-beta | Smad signaling and fibrosis |
| TGFBR2 | TGF-beta receptor type 2; binds TGF-beta | TGF-beta signaling and cancer |
| INSR | Insulin receptor; binds insulin | Metabolic disorders and diabetes |
| CSF2RB | Cytokine receptor common beta chain; binds GM-CSF | Immune cell signaling |
| IL2RA | Interleukin-2 receptor alpha; binds IL-2 | T-cell signaling and immunotherapy |
| TSPAN8 | Tetraspanin 8; interacts with EGFR | Tumor progression and metastasis |
| STAT3 | Signal transducer; downstream of receptor binding | Transcription factor in cancer |
| SMAD2 | Downstream effector of TGF-beta receptor | TGF-beta signaling |
| SMAD3 | Downstream effector of TGF-beta receptor | TGF-beta signaling |
| ARRB1 | Beta-arrestin 1; regulates GPCR signaling | GPCR desensitization |
| GNAI1 | G protein subunit alpha i1; couples to GPCRs | GPCR signal transduction |
How Is signaling receptor binding Regulated?
Signaling receptor binding is regulated at multiple levels. Receptor availability is controlled by gene expression, trafficking and post-translational modifications [1,3]. Ligand concentration and affinity are modulated by synthesis, secretion and degradation [2,4]. Desensitization mechanisms, such as phosphorylation by GPCR kinases and arrestin recruitment, terminate binding and signaling. In RTK signaling, phosphatases and ubiquitin ligases negatively regulate receptor activity. Nuclear receptor binding is regulated by coactivator and corepressor proteins. Additionally, viral infections can alter receptor binding through immune evasion strategies. These regulatory layers ensure that signaling receptor binding is context-dependent and reversible.
signaling receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Cancer (lung, breast, glioblastoma) | Knockout or point mutation in cancer cell lines |
| IGF1R | Cancer, growth disorders | Knockout and overexpression models |
| NR3C2 | Hypertension, pseudohypoaldosteronism | Point mutation knock-in in cell lines |
| GHRHR | Growth hormone deficiency | Knockout and point mutation models |
| TGFBR2 | Fibrosis, cancer | Knockout and knock-in of ligand-binding domain |
Cancer
Dysregulated signaling receptor binding is a hallmark of many cancers. Overexpression or mutation of RTKs such as EGFR and IGF1R leads to constitutive activation of proliferative and survival pathways [3,5]. For example, EGFR signaling promotes nuclear translocation of TSPAN8, enhancing tumor progression via STAT3-mediated transcription. Targeting receptor-ligand interactions with monoclonal antibodies or tyrosine kinase inhibitors is a major therapeutic strategy.
Endocrine and metabolic disorders
Altered binding of hormones to their receptors underlies endocrine diseases. Mutations in the mineralocorticoid receptor (NR3C2) affect aldosterone binding and cause hypertension or electrolyte imbalances. Defects in growth hormone-releasing hormone receptor (GHRHR) signaling lead to growth hormone deficiency. Insulin receptor binding defects contribute to insulin resistance and diabetes.
Infectious diseases
Many viruses exploit signaling receptor binding for entry. The interaction between viral proteins and host receptors determines tropism and pathogenesis. For example, interferon-gamma related binding in fish models reveals unique receptor complexes and signaling pathways that may inform antiviral immunity. Understanding these interactions aids in developing entry inhibitors and vaccines.
Immune and inflammatory diseases
Cytokine receptor binding is central to immune regulation. Aberrant IL-2 receptor binding can lead to autoimmune diseases or immunodeficiency. TGF-beta receptor binding and Smad signaling are involved in fibrosis and immune suppression. Targeting these interactions is a therapeutic approach for inflammatory conditions [7,8].
From signaling receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of receptor binding affect downstream signaling? | CRISPR knockout of receptor gene [1,3] |
| Does a specific point mutation alter ligand affinity? | CRISPR point mutation knock-in [4,6] |
| Can a tagged receptor be used to track binding dynamics? | Tagged knock-in (e.g., GFP or HA tag) [1,5] |
| Does overexpression of ligand enhance signaling? | CRISPR overexpression (e.g., CRISPRa) [3,7] |
| Which genes are essential for receptor-mediated viral entry? | Genome-wide CRISPR knockout library screening |
| How does a disease-associated mutation affect receptor function? | Patient-derived cells with CRISPR correction [5,8] |
How to Study the signaling receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and kinetics of ligand-receptor interaction | GPCR pharmacology |
| Surface plasmon resonance (SPR) | Real-time binding kinetics | RTK-ligand interactions |
| Cryo-EM | High-resolution structure of receptor-ligand complex | GPCR signaling complexes |
| cAMP assay | G protein activation downstream of GPCR binding | GPCR functional screening |
| Phospho-ERK immunoblot | MAPK pathway activation | RTK signaling [3,5] |
| CRISPR knockout screen | Genes required for receptor-mediated signaling | Viral entry, cancer dependencies [2,5] |
| Luciferase reporter | Transcriptional response to receptor activation | Nuclear receptor and Smad signaling [4,8] |
| Co-immunoprecipitation | Physical interaction between receptor and ligand or effector | Complex assembly [5,7] |
Binding assays
Direct measurement of signaling receptor binding is performed using radioligand binding assays, surface plasmon resonance (SPR), isothermal titration calorimetry (ITC) and fluorescence polarization. These methods quantify affinity (Kd), kinetics (kon, koff) and specificity [1,3]. For GPCRs, radioligand binding with agonists or antagonists is standard.
Structural biology
X-ray crystallography and cryo-electron microscopy (cryo-EM) provide atomic-level views of receptor-ligand complexes. These techniques reveal the binding pocket, conformational changes and interaction interfaces, as demonstrated for GPCR signaling complexes. Structural insights guide drug design and mutagenesis studies [1,4].
Cell-based signaling assays
Functional consequences of receptor binding are measured using reporter gene assays, second messenger quantification (cAMP, IP3, calcium), phosphorylation-specific immunoblotting and luciferase-based pathway reporters [1,3,5]. These assays link binding to downstream cellular responses [5,7].
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens identify genes that modulate signaling receptor binding and downstream signaling. For example, screens can uncover host factors required for viral receptor binding or for growth factor signaling [2,5]. These approaches are powerful for discovering novel components of receptor pathways.
How CRISPR Can Be Used to Study GO:0005102 signaling receptor binding
Knockout
CRISPR knockout is used to eliminate receptor or ligand genes to determine their necessity in signaling receptor binding. For example, knocking out EGFR or IGF1R abolishes ligand-induced signaling and downstream phenotypes [3,5]. Knockout models are also used in genome-wide screens to identify host factors for viral entry.
Point Mutation
CRISPR point mutation introduces specific amino acid changes in receptor binding domains to test the effect on ligand affinity or specificity. This is valuable for modeling disease-associated mutations, such as those in NR3C2 or GHRHR, and for dissecting binding determinants [4,6].
Knock-in
Knock-in of tagged receptors (e.g., GFP, HA, or luciferase) allows real-time tracking of receptor expression, localization and binding dynamics. Knock-in of reporter genes downstream of receptor activation enables sensitive readouts of signaling [1,5].
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression is used to increase receptor or ligand levels to study gain-of-function effects, ligand-independent activation, or to enhance signal output in otherwise low-responding cells [3,7].
How EDITGENE Supports signaling receptor binding Research
Researchers studying signaling receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor-ligand interactions, downstream signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to enable these investigations with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for signaling receptor binding research.
Frequently Asked Questions About signaling receptor binding
What is GO:0005102 signaling receptor binding?
GO:0005102 is a Gene Ontology molecular function term defined as binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.
What genes are involved in signaling receptor binding?
Genes encoding receptors and their ligands, such as ADRB2, EGFR, IGF1R, NR3C2, GHRHR, IFNGR1, TGFBR1 and TGFBR2, are involved in signaling receptor binding [1,3,4,6,7,8].
What is the difference between signaling receptor binding and receptor activity?
Signaling receptor binding (GO:0005102) describes the binding event itself, while receptor activity refers to the downstream signaling function initiated by the receptor after ligand binding.
How is signaling receptor binding studied experimentally?
It is studied using binding assays (radioligand, SPR), structural biology (cryo-EM), cell-based signaling assays, and CRISPR-based genetic screens [1,2,3,5].
What diseases are associated with defects in signaling receptor binding?
Diseases include cancer, endocrine disorders, immune deficiencies and viral infections, linked to mutations or dysregulation of receptors such as EGFR, IGF1R, NR3C2 and GHRHR [3,4,5,6,7].
Can CRISPR be used to study signaling receptor binding?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are widely used to dissect receptor-ligand interactions and their downstream effects [2,4,5,6].
What are the synonyms for GO:0005102?
The synonyms are receptor-associated protein activity, receptor binding, and receptor ligand.
Which receptors are examples of signaling receptor binding?
Examples include GPCRs, receptor tyrosine kinases (RTKs), cytokine receptors, nuclear hormone receptors and viral entry receptors [1,2,3,4,7].
How does signaling receptor binding initiate signal transduction?
Ligand binding induces conformational changes in the receptor, leading to activation of downstream effectors such as G proteins, kinases or transcription factors [1,3,4,8].
What services does EDITGENE offer for studying signaling receptor binding?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening and bioinformatics services to study signaling receptor binding [1,2,5,8].
Conclusion
Signaling receptor binding (GO:0005102) is a fundamental molecular function that governs how cells communicate with their environment. It encompasses the specific interaction between ligands and receptors, initiating diverse signaling cascades with profound implications for physiology and disease [1,2,3,4]. Understanding the mechanisms, key genes and regulatory networks of signaling receptor binding is essential for developing targeted therapies in cancer, endocrine disorders, infectious diseases and immune dysfunction [5,6,7,8]. Advances in CRISPR-based models and screening technologies continue to accelerate discoveries in this field, offering new opportunities for therapeutic intervention.
References
- 1. Hilger D et al.. 2018. Structure and dynamics of GPCR signaling complexes.. Nat Struct Mol Biol 25(1):4-12 PMID: 29323277
- 2. Boulant S et al.. 2015. Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis.. Viruses 7(6):2794-815 PMID: 26043381
- 3. Hakuno F et al.. 2018. IGF1 receptor signaling pathways.. J Mol Endocrinol 61(1):T69-T86 PMID: 29535161
- 4. Fuller PJ et al.. 2019. Mechanisms of Mineralocorticoid Receptor Signaling.. Vitam Horm 109:37-68 PMID: 30678864
- 5. Lu X et al.. 2022. EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription.. Cell Res 32(4):359-374 PMID: 35197608
- 6. Halmos G et al.. 2023. Signaling mechanism of growth hormone-releasing hormone receptor.. Vitam Horm 123:1-26 PMID: 37717982
- 7. Shibasaki Y et al.. 2024. Characterization of fish-specific IFNγ-related binding with a unique receptor complex and signaling through a novel pathway.. FEBS Open Bio 14(4):532-544 PMID: 38321830
- 8. Wrana JL. 2000. Crossing Smads.. Sci STKE 2000(23):re1 PMID: 11752591
